Prostate cancer, the PSA test and academic detailing in Australian general practice: an economic evaluation

Abstract

Objectives: To evaluate whether introduction of a national education program for GPs to improve decision making relating to the use of prostate specific antigen (PSA) testing for screening represents ‘value‐for‐money’ from the perspective of the Australian Government.Methods: The annual equivalent costs and consequences of a proposed national program in steady state operation are estimated for Australia using 1996 as the reference year. Because of the controversy about the efficacy of screening using PSA testing, two scenarios are modelled. Uncertainty in the model is examined using Monte Carlo simulation methods.Results: In scenario one, our model predicts that the national program would cost $12.5 million (gross) or $6.6 million (net), would reduce the burden of disease by 4.7% of total DALYs due to prostate cancer in those aged 70 and over, with no loss of life and an incremental cost effectiveness ratio (ICER) of $16,000/DALY (gross) and $8,500/DALY (net). In scenario two, the proposed program would cost $12.5 million (gross) or $7.1 million (net), would reduce the burden of disease by 3.1% of total, increase by 44 the prostate cancer deaths at an ICER of $24,000/DALY (gross) and $14,000/DALY (net).Conclusions: These findings, with an overall health benefit at moderate cost and acceptable ICER, support the case for consideration of a national education program on the assumption that prostate cancer screening over age 70 does not reduce mortality. A larger Australian study currently being conducted should provide stronger evidence on the value of implementing a full national program.